Type2 Diabetes
Conditions
Interventions
The group of Dapagliflozin 5mg treatment.
The group of standard treatment(other than SGLT-2 inhibitor treatment)
Sponsors
Dokkyo Medical University Nikko Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (a)Type 2 diabetes patients with HbA1c>7.0% (b)Diabetic nephropathy stage<4
Exclusion criteria
Exclusion criteria: (a) Patients with type 1 diabetes mellitus (b) Patients with a medical history of hypersensitivity to any of the ingredients of dapagliflozin (c) Patients with severe ketosis or diabetic coma or pre-coma (d) Patients who have severe infection, are pre- or postoperative, or have sustained serious trauma (e) Patients with severe impaired liver function (f) Patients who are susceptible to dehydration (g) Patients with urinary tract infection or genital infection (h) Patients with a history of cerebrovascular disease within the last 3 months (i) Women who are pregnant or breastfeeding or who may be pregnant (j) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 mL (k) Patients on warfarin or a novel oral anticoagulant (NOAC) (dabigatran, rivaroxaban, edoxaban, or apixaban) (l) Patients otherwise deemed to be unsuitable for the clinical study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whole blood transit time and the difference from baseline at 48h after Dapagliflozin treatment, as assessed using microchannel array flow analyzer equipped with BK7-7-7D chip.nowo | — |
Secondary
| Measure | Time frame |
|---|---|
| a)Leukocyte activation (adhesive leukocyte count as determined using the MC-FAN with DKAMCM1-60-7-4.5Denrollment b)Hs-CRP C)Oxidative stress as determined by the d-ROMs test d)Complete blood count | — |
Countries
Japan
Contacts
Public ContactYuki Nakatani
Dokkyo Medical University Nikko Medical Center Diabetes and Endcrinology
Outcome results
None listed